Green Thumb Reports Strong Q1 Net Income, Expands Share Buyback to $150M, and Highlights Major Marijuana Rescheduling

summarizeSummary

Green Thumb Industries reported strong Q1 net income driven by a one-time settlement, expanded its share repurchase program to $150 million, and highlighted the highly positive implications of medical marijuana rescheduling to Schedule III.

check_boxKey Events

• Q1 2026 Financial Performance

  Revenue increased 7% to $300.19 million, while net income attributable to Green Thumb Industries Inc. surged 85% to $15.40 million, resulting in basic EPS of $0.07. Gross profit remained flat at $143.65 million, with gross margin declining to 48% from 51% due to licensing fees and price compression. Operating income decreased by 4%.

• Share Repurchase Program Expanded

  On April 21, 2026, the Board of Directors authorized an expansion of the share repurchase program from $50 million to $150 million. During Q1 2026, the company repurchased approximately 6.05 million Subordinate Voting Shares for $33.3 million at an average price of $5.51 per share.

• Marijuana Rescheduling to Schedule III

  On April 23, 2026, the U.S. Department of Justice issued a Final Order rescheduling FDA-approved and state-regulated medical marijuana products to Schedule III. This is a significant regulatory change expected to eliminate the IRC Section 280E tax burden for qualifying medical marijuana businesses.

• Arbitration Settlement Boosts Net Income

  The company received a $17.0 million arbitration settlement from Ascend Wellness Holdings Inc. on February 12, 2026, which was a key driver for the significant increase in Q1 net income.

auto_awesomeAnalysis

Green Thumb Industries reported mixed operational results for Q1 2026, with revenue growth of 7% but a slight decline in operating income and gross margin. However, net income and EPS saw substantial increases, primarily driven by a one-time $17.0 million arbitration settlement and income from an equity method investment. Critically, the company announced two significant subsequent events: a substantial expansion of its share repurchase program from $50 million to $150 million, signaling strong management confidence and commitment to shareholder returns. More importantly, the U.S. Department of Justice's Final Order to reschedule medical marijuana products to Schedule III is a potentially transformative development for the cannabis industry, as it is expected to eliminate the punitive IRC Section 280E tax burden for qualifying state medical marijuana licenses, which could significantly boost future profitability for Green Thumb. This filing provides the full financial details following a preliminary 8-K announcement earlier today.